WO2000053219A3 - Compositions et techniques permettant de traiter le cancer et les troubles hyperproliferatifs - Google Patents

Compositions et techniques permettant de traiter le cancer et les troubles hyperproliferatifs Download PDF

Info

Publication number
WO2000053219A3
WO2000053219A3 PCT/US2000/006320 US0006320W WO0053219A3 WO 2000053219 A3 WO2000053219 A3 WO 2000053219A3 US 0006320 W US0006320 W US 0006320W WO 0053219 A3 WO0053219 A3 WO 0053219A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferation
methods
compositions
growth
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/006320
Other languages
English (en)
Other versions
WO2000053219A2 (fr
Inventor
John W Holaday
Antonio Ruiz
John Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/266,543 external-priority patent/US6805865B1/en
Application filed by Entremed Inc filed Critical Entremed Inc
Priority to CA002364503A priority Critical patent/CA2364503A1/fr
Priority to JP2000603708A priority patent/JP2002538219A/ja
Priority to KR1020017011491A priority patent/KR20010102556A/ko
Priority to EP00912209A priority patent/EP1156824A2/fr
Priority to AU33972/00A priority patent/AU776473C/en
Publication of WO2000053219A2 publication Critical patent/WO2000053219A2/fr
Publication of WO2000053219A3 publication Critical patent/WO2000053219A3/fr
Anticipated expiration legal-status Critical
Priority to AU2004237888A priority patent/AU2004237888B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des techniques efficaces pour déclencher une réponse immunitaire permettant d'inhiber une prolifération cellulaire indésirable ou anormale, notamment une prolifération cellulaire endothéliale et une angiogénèse associée à une néovascularisation et une croissance tumorale. Ces compositions comprennent une protéine naturelle ou synthétique, un peptide, ou un fragment de protéine contenant la totalité d'un facteur de croissance ou une partie active de celui-ci dans un excipient pharmaceutiquement acceptable. Les facteurs de croissance préférés sont le facteur de croissance de fibroblaste basique et le facteur de croissance endothélial vasculaire. Les techniques consistent à administrer les compositions précitées à un animal ou à un humain, en quantité suffisante pour déclencher une réponse immunitaire. Ces techniques sont utiles pour traiter des maladies et des troubles induits par une prolifération cellulaire indésirable ou incontrôlée, telle que le cancer, notamment lorsque cette prolifération cellulaire incontrôlée est influencée par la présence de facteurs de croissance. L'administration de ces compositions à un humain empêche la croissance ou l'extension des tumeurs.
PCT/US2000/006320 1999-03-11 2000-03-10 Compositions et techniques permettant de traiter le cancer et les troubles hyperproliferatifs Ceased WO2000053219A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002364503A CA2364503A1 (fr) 1999-03-11 2000-03-10 Compositions et techniques permettant de traiter le cancer et les troubles hyperproliferatifs
JP2000603708A JP2002538219A (ja) 1999-03-11 2000-03-10 癌及び高増殖性疾患治療用の組成物及び方法
KR1020017011491A KR20010102556A (ko) 1999-03-11 2000-03-10 암 및 과증식성 장애의 치료 조성물 및 치료방법
EP00912209A EP1156824A2 (fr) 1999-03-11 2000-03-10 Compositions et techniques permettant de traiter le cancer et les troubles hyperproliferatifs
AU33972/00A AU776473C (en) 1999-03-11 2000-03-10 Compositions and methods for treating cancer and hyperproliferative disorders
AU2004237888A AU2004237888B2 (en) 1999-03-11 2004-12-09 Compositions and methods for treating cancer and hyperproliferative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/266,543 US6805865B1 (en) 1993-05-27 1999-03-11 Compositions and methods for treating cancer and hyperproliferative disorders
US09/266,543 1999-03-11

Publications (2)

Publication Number Publication Date
WO2000053219A2 WO2000053219A2 (fr) 2000-09-14
WO2000053219A3 true WO2000053219A3 (fr) 2001-01-25

Family

ID=23015010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006320 Ceased WO2000053219A2 (fr) 1999-03-11 2000-03-10 Compositions et techniques permettant de traiter le cancer et les troubles hyperproliferatifs

Country Status (6)

Country Link
EP (1) EP1156824A2 (fr)
JP (1) JP2002538219A (fr)
KR (1) KR20010102556A (fr)
AU (2) AU776473C (fr)
CA (1) CA2364503A1 (fr)
WO (1) WO2000053219A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814744B1 (fr) * 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
ITRM20010088A1 (it) 2001-02-21 2002-08-21 Idi Irccs Peptide in grado di inibire l'attivita' del fattore di crescita derivato dalle piastrine (pdgf-bb) e del fattore di crescita derivato dai fi
US8021658B2 (en) 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
CN105664147A (zh) * 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
FR2990352A1 (fr) * 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
WO2020110154A1 (fr) * 2018-11-30 2020-06-04 Bharat Biotech International Limited Vaccin thérapeutique chimérique
CU24637B1 (es) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027635A1 (fr) * 1993-05-27 1994-12-08 Entremed, Inc. Compositions et procedes de traitement du cancer et de maladies hyperproliferatives
EP0657175A2 (fr) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Vaccin comprenant un facteur de croissance de l'épiderme autologue et son utilisation
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
WO1999045018A1 (fr) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Immunisation active contre les antigenes associes a l'angiogenese

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027635A1 (fr) * 1993-05-27 1994-12-08 Entremed, Inc. Compositions et procedes de traitement du cancer et de maladies hyperproliferatives
EP0657175A2 (fr) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Vaccin comprenant un facteur de croissance de l'épiderme autologue et son utilisation
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
WO1999045018A1 (fr) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Immunisation active contre les antigenes associes a l'angiogenese

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
patent abstracts of japan vol. 1998, n° 04, 31 March 1998 (1998-03-31) *
PLUM S M ET AL: "Vaccination with peptide to the heparin binding domain of bFGF conjugated to liposomes inhibits bFGF induced neovascularization.", March 1998, PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, VOL. 39, PAGE(S) 8, 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH;NEW ORLEANS, LOUISIANA, USA; MARCH 28-APRIL 1, 1998, MARCH, 1998, ISSN: 0197-016X, XP000929460 *
TALARICO D ET AL: "PROTECTION OF MICE AGAINST TUMOR GROWTH BY IMMUNIZATION WITH AN ONCOGENE-ENCODED GROWTH FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 87, no. 11, 1990, 1990, pages 4222 - 4225, XP002143558, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2004237888A1 (en) 2005-01-13
KR20010102556A (ko) 2001-11-15
CA2364503A1 (fr) 2000-09-14
WO2000053219A2 (fr) 2000-09-14
AU776473C (en) 2005-04-14
AU3397200A (en) 2000-09-28
JP2002538219A (ja) 2002-11-12
AU776473B2 (en) 2004-09-09
AU2004237888B2 (en) 2008-04-10
EP1156824A2 (fr) 2001-11-28

Similar Documents

Publication Publication Date Title
WO2001027079A3 (fr) Compositions et methodes d'utilisation de ligands liant des elements de la voie de coagulation sanguine pour le traitement du cancer et de maladies induites par le processus d'angiogenese
CN105939723B (zh) 前列腺癌治疗用组合物
AU2001268680A1 (en) Methods and compositions for the treatment of peripheral artery disease
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
WO2001039762A3 (fr) Methodes de traitement de tumeurs
EP0702563A4 (fr) Compositions et procedes de traitement du cancer et de maladies hyperproliferatives
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
DE69836199D1 (de) Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung
NO911854D0 (no) Fremgangsmaate for fremstilling av peptid-derivater.
CA2378943A1 (fr) Analogue superactif de la somatostatine porcine
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
EP0797999A3 (fr) Formulations de protéine d'obésité
GR3036774T3 (en) Compositions containing G-CSF and TNF binding protein.
ZA915656B (en) Heterocyclic compounds
MX9701820A (es) Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.
NZ511280A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
EP0281070A3 (fr) Composé pharmaceutique pour le traitement du cancer
MXPA05003634A (es) Extracto con actividad anti-tumoral y anti-venenosa.
Longnecker Hormones and pancreatic cancer
Vance et al. Endocrine and clinical effects of leuprolide in prostatic cancer
WO2001044294A3 (fr) Compositions et procedes d'inhibition de la proliferation de cellules endotheliales
EP0821969A3 (fr) Composition médicale contenant du TCF-II
MXPA02000915A (es) Composiciones que contienen agentes activos derivados de musculo.
CA2327382A1 (fr) Inhibiteurs de neovascularisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2364503

Country of ref document: CA

Ref country code: CA

Ref document number: 2364503

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020017011491

Country of ref document: KR

Ref document number: 33972/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 603708

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000912209

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017011491

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000912209

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 33972/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011491

Country of ref document: KR